An EBV-Positive Lymphoproliferative Disorder after Therapy with Alemtuzumab

To the Editor: Alemtuzumab (Campath-1H) is a humanized monoclonal antibody directed against CD52, a glycosylated peptide antigen that is expressed on normal lymphocytes and highly expressed on chronic lymphocytic leukemia cells. It has been shown to have clinically significant activity in T-cell chronic lymphocytic leukemia. The primary treatment-related adverse event that has been reported is the development of opportunistic infections secondary to the T-cell immunodeficiency. 1 We report a case of an Epstein–Barr virus (EBV)–positive lymphoproliferative disorder occurring after the use of alemtuzumab. An 80-year-old woman had received the diagnosis of CD4-positive T-cell chronic lymphocytic leukemia eight years previously. There was . . .